New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor

xlomafota13 shared this article with you from Inoreader New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor Via Association française pour l'étude du cancer Bull Cancer. 2021 Feb;108(2):142-144. doi: 10.1016/j.bulcan.2020.12.006. Epub 2021 Jan 30. NO ABSTRACT PMID:33531153 | DOI:10.1016/j.bulcan.2020.12.006 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.